Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients
Galal, G., Abd-El-Fatah, M., Kamel, S. (2018). Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients. EKB Journal Management System, 22(3), 245-251. doi: 10.21608/smj.2018.34099
Ghada Galal; Mahmoud Abd-El-Fatah; Samar Hussein Kamel. "Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients". EKB Journal Management System, 22, 3, 2018, 245-251. doi: 10.21608/smj.2018.34099
Galal, G., Abd-El-Fatah, M., Kamel, S. (2018). 'Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients', EKB Journal Management System, 22(3), pp. 245-251. doi: 10.21608/smj.2018.34099
Galal, G., Abd-El-Fatah, M., Kamel, S. Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients. EKB Journal Management System, 2018; 22(3): 245-251. doi: 10.21608/smj.2018.34099

Non-invasive methods for diagnosis of hepatic fibrosis in chronic hepatitis B patients

Sohag Medical Journal
Article 29, Volume 22, Issue 3, October 2018, Page 245-251  XML PDF (87.18 K)
Document Type: Original Article
DOI: 10.21608/smj.2018.34099
View on SCiNiTO View on SCiNiTO
Authors
Ghada Galal1; Mahmoud Abd-El-Fatahorcid 2; Samar Hussein Kamel2
1Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.
2Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University
Abstract
Non-invasive markers for assessing liver fibrosis have been developed, and they are frequently used in clinical practice. They have been validated in different studies, and some were found to be highly accurate compared with liver biopsies which have always been used as the standard reference method for evaluating the accuracy of non-invasive methods1.The performance of a non-invasive diagnostic method is evaluated by calculation of the area under the receiver operator characteristic curve (AUROC)2.
Supplementary Files
References
  1. Castera L (2011):  “Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease,” Best Practice and Research: Clinical Gastroenterology; vol. 25, no. 2, pp. 291-303.
  2. Mehta SH, Lau B, Afdhal NH, Thomas DL (2009):  Exceeding the limits of liver histology markers. J Hepatol; 50:36-41.
  3. Fontana  RJ, Lok  AS (2002): Noninvasive monitoring of patients with chronic hepatitis C. Hepatology; 36:S57-64.
  4. Sandrin L, Catheline S, Tanter M, Hennequin X, Fink M  (1999): Time-resolved pulsed elastography with ultrafast ultrasonic imaging. Ultrason Imaging; 21(4):259-72.
  5. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E  (2008):  Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis.PLoS One. 2012; 7(9): e44930.
  6. Blomley MJ, Lim AK, Harvey CJ, Patel N, Eckersley RJ, Basilico R, Heckemann R, Urbank A, Cosgrove DO, Taylor-Robinson SD (2003): Liver microbubble transit time compared with histology and Child - Pugh score in diffuse liver disease. A cross sectional study. Gut; 52:1188-93.
  7. Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K (2010):  Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int; 30(4):538-45.
  8. Rifai K, Cornberg J, Mederacke I, Bahr MJ, Wedemeyer H, Malinski P, Bantel H, Boozari B, Potthoff A, Manns MP, Gebel M (2011):  Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI) Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Jun; vol. 43:491-7.
  9. Taouli B, Ehman RL, Reeder SB (2009): Advanced MRI methods for assessment of chronic liver disease. AJR; 193:14-27.
  10. Zhou K and Lu LG (2009): Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases; 10(1):7-14.
  11. Grigorescu M (2006): Noninvasive biochemical markers of liver fibrosis. Journal of gastrointestinal and liver diseases; 15(2):149-59.
  12. Gressner OA, Weiskirchen R, Gressner AM (2007): Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver dependent malfunction tests. ClinChimActa; 381:107-13.
  13. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L (2010): Circulating markers of liver fibrosis progression. ClinicaChimicaActa , 411(15-16):1009-17. 
  14. Lieber CS, Weiss DG, Paronetto F (2008): Veterans Affairs Cooperative Study 391 Group: Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol ClinExp Res; 32(6):1031-9. 
  15. Sun J (2010): Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. Journal of Signal Transduction; 2010:1-7.
  16. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A (1997):  Dual expression of matrix protease -2 and membrane type I-matrix proteinase in fibrotic human livers.Hepatology; 26:1521-9.
  17. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ (1999): Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non invasive markers of liver disease inchronic hepatitis C: comparison using ROC analysis. Dig Dis Sci; 44:624-30.  
  18. Bataller R, Brenner DA (2005):  Liver Fibrosis. The Journal of Clinical Investigation; 115(2):209-18.
  19. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I (2006):  Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease. Liver Int; 26:864-71.
  20. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P (2000): Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J GastroenterolHepatol; 12(9):989-93.
  21. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE (2009): A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol; 50(2):370-6.
  22. Kropf J, Gressner AM, Negwer A (1988): Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clinical Chemistry; 34:2026-30.
  23. Gressner OA and Gressner AM (2008): Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver International; 28:1065-79.
  24. Camps J, Marsillach J, Joven J (2009): Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol; 15(16):1929-33.
  25. Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler K (2009): Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology; 49(4):1257-66.
  26. Giboney PT (2005): Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician; 71(6):1105-10. 
  27. Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL (2008): Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests. Aliment PharmacolTher; 28(10):1188-98.
  28. Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, Mendez-Navarro J, Chen WC, Jilg N, Zhao H, Goto K, Zhang L, Brockman MA, Schuppan D, Chung RT (2010):  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology; 53:726-36.
  29. Rossi E, Adams LA, Bulsara M, Jeffrey GP (2007): Assessing liver fibrosis with serum marker models.ClinBiochem Rev; 28(1):3-10.
  30. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP (2010): ANRS HC EP 23 Fibrostar study group Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. ClinChimActa; 411(1-2):86-91.
  31. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M (2006): APRICOT Clinical Investigators:Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology; 43:1317-25. 
  32. Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T  (2004):  Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. ClinChem Lab Med; 42(3):323-33. 
  33. Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ (2003): Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol; 9(12):2796-800.
  34. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, Maïga MY, Gallois Y, Calès P(1998): Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol; 28:439-46. 
  35. Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A, Michalak S, Hunault G, Chaigneau J, Sawadogo A, Lunel F (2008): A family of blood tests for liver fibrosis. GastroenterolClinBiol; 32:40-51.
  36. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ  (2005): Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol; 100: 616-23.
  37. Sebastiani G, Vario A, Guido M, Alberti A (2007): Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol; 13: 525-31.
  38. Liu XD, Wu LJ, Liang J. Zhang T, and Sheng QS (2012): Globulin-platelet model predict minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol; 18:2784-92.
  39. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C (2005): Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology; 42(2):282-92.
  40. Callewaert N, Vlierberghe HV, Hecke AV, Laroy W, Delanghe J, Contreras R (2004): Non invasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Medicine; 10:429-34. 
  41. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE (2005): Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology; 41:1376-82.
  42. Rockey DC, Bissell DM (2006): Noninvasive measures of liver fibrosis. Hepatology; 43:S113-20.
 

 

 

 

 

 

 

Statistics
Article View: 228
PDF Download: 296